Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI)
€ 88.2 0.4 (0.46%) Market Cap: 4.51 Bil Enterprise Value: 4.55 Bil PE Ratio: 33.53 PB Ratio: 8.48 GF Score: 88/100

Q2 2022 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

Jul 27, 2022 / 01:00PM GMT
Release Date Price: €57.25 (-4.42%)
Javier Lopez;Belmonte Encina
Laboratorios Farmaceuticos Rovi, S.A. - First Deputy Chairman & CFO

Good afternoon, and welcome, everybody, to this first half results vital meeting which will start in a moment. This is Javier Lopez-Belmonte, Rovi's Vice President and Chief Financial Officer. Please let me introduce Rovi's attendees today, Juan Lopez-Belmonte, Chairman and CEO; Marta Campos, Head of Investor Relations; and myself.

At the end of the presentation, a question-and-answer session will commence. If you want to ask any questions during the presentation, please do not hesitate to send them through the question button on the platform. Thank you for your presence here today. And let's now start the presentation. I Mr. Juan Lopez-Belmonte the floor.

Juan Lopez;Belmonte Encina
Laboratorios Farmaceuticos Rovi, S.A. - President, CEO & Director

Thank you, Javier, and welcome to everybody. I'm happy to present our first half 2022 results. In these exceptional times, robust performance during the period has been

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot